Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
China · Delayed Price · Currency is CNY 28.63
+0.27 (0.95%)
Aug 20, 2026, 3:00 PM CST
SHA:600976 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,392 | 5,150 | 6,394 | 9,916 | 7,551 | 11,989 | |
Market Cap Growth | -32.03% | -19.46% | -35.52% | 31.31% | -37.01% | 207.81% |
Enterprise Value | 3,462 | 4,163 | 5,531 | 9,131 | 6,672 | 11,258 |
Last Close Price | 28.63 | 32.66 | 39.70 | 60.83 | 45.62 | 71.09 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.75 | 14.31 | 17.65 | 19.02 | 18.50 | 39.27 |
Forward PE | - | 10.79 | 10.45 | 16.65 | 16.11 | 30.20 |
PS Ratio | 1.38 | 1.53 | 1.82 | 2.35 | 2.07 | 3.63 |
PB Ratio | 1.62 | 1.92 | 2.61 | 4.39 | 4.05 | 8.06 |
P/TBV Ratio | 1.65 | 1.96 | 2.66 | 4.47 | 4.13 | 8.28 |
P/FCF Ratio | 20.13 | 29.62 | 56.10 | 48.63 | 51.06 | 62.52 |
P/OCF Ratio | 12.94 | 18.76 | 27.29 | 36.95 | 34.98 | 48.36 |
PEG Ratio | - | 1.46 | 1.46 | 1.46 | 1.46 | 1.46 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.09 | 1.24 | 1.58 | 2.17 | 1.83 | 3.41 |
EV/EBITDA Ratio | 11.89 | 15.88 | 37.78 | 26.38 | 22.62 | 47.72 |
EV/EBIT Ratio | 14.58 | 18.54 | 49.56 | 29.16 | 25.39 | 54.27 |
EV/FCF Ratio | 15.87 | 23.95 | 48.53 | 44.78 | 45.11 | 58.71 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.05 | 0.07 | 0.05 | 0.03 | 0.05 |
Debt / EBITDA Ratio | 0.32 | 0.47 | 1.15 | 0.32 | 0.18 | 0.30 |
Debt / FCF Ratio | 0.43 | 0.72 | 1.54 | 0.56 | 0.36 | 0.37 |
Net Debt / Equity Ratio | -0.35 | -0.40 | -0.38 | -0.39 | -0.43 | -0.52 |
Net Debt / EBITDA Ratio | -3.31 | -4.11 | -6.43 | -2.56 | -2.74 | -3.26 |
Net Debt / FCF Ratio | -4.35 | -6.20 | -8.26 | -4.34 | -5.46 | -4.01 |
Asset Turnover | 0.72 | 0.77 | 0.83 | 1.11 | 1.16 | 1.25 |
Inventory Turnover | 4.21 | 4.40 | 4.56 | 5.60 | 7.06 | 8.34 |
Quick Ratio | 1.29 | 1.36 | 1.20 | 1.18 | 1.16 | 1.17 |
Current Ratio | 1.65 | 1.58 | 1.49 | 1.49 | 1.50 | 1.41 |
Return on Equity (ROE) | 12.25% | 14.25% | 15.63% | 25.39% | 24.22% | 21.77% |
Return on Assets (ROA) | 3.35% | 3.19% | 1.65% | 5.14% | 5.22% | 4.92% |
Return on Invested Capital (ROIC) | 12.46% | 13.50% | 7.26% | 23.62% | 27.42% | 25.02% |
Return on Capital Employed (ROCE) | 8.40% | 8.00% | 4.40% | 13.50% | 13.80% | 13.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.20% | 6.99% | 5.67% | 5.26% | 5.40% | 2.55% |
FCF Yield | 4.97% | 3.38% | 1.78% | 2.06% | 1.96% | 1.60% |
Dividend Yield | 3.16% | 2.76% | 2.27% | 1.97% | 2.19% | 1.13% |
Payout Ratio | 43.73% | 39.27% | 51.83% | 29.95% | 30.39% | 19.20% |
Buyback Yield / Dilution | -0.66% | 0.23% | 0.49% | -0.43% | -0.26% | 1.35% |
Total Shareholder Return | 2.50% | 2.98% | 2.75% | 1.54% | 1.93% | 2.48% |